Thus, the activity of CXCR1/CXCR2 ligands in the MM bone marrow microenvironment is antitumor in MM, while activation of CXCR1 on MM cells is protumor, unlike activation of CXCR2 on MM cells. This evidence concerns the gene CXCR2 and Miyoshi myopathy.